Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
Garbage.....
-
All the great news in the world is useless if they don’t actually release the info.
-
Without PR this is gonna bleed out. Look for sub $3 tomorrow.
-
Power hour
-
Out, 8500 @ $3.48. .... Will look to re-enter at $2.90 range. Shorts have their hooks in this one good. This has good potential but too many other plays available to sit in this stagnant bear pool..Good Luck to ya Bulls
-
Without PR this is going to be pulled down every day by Shorts.
-
JuiceWrldStocks is worried about losing his $600 stimulus investment. All those damn tears..
-
Back in this bad boy
-
I’m all in let’s get it
-
Lol might as well throw one last Offering into the mix
-
Sold all 17k at $3.05. This is going to plummet at open. Look to rebuy at $1.85
-
Shorts attacked everywhere!!!
-
Unless news is released this Is going back to u 2
-
Anyone else seeing it jump from 3.18 to 3.50 right now?
-
I’m out be back in at a lower price
-
That massive dip was unfortunately a huge boost to Shorts ..gonna need some PR to get this to climb
-
They are en route to find partner for IND submission, once find a partner who can promote and sell their covid nasal spray.
Some more interesting stuff around their ongoing tests under COVID-19https://finance.yahoo.com/news/atossa-therapeutics-president-ceo-dr-143000932.html
-
Coming from the CEO at $ATOS -
During 2020, we completed successful in-vitro testing followed by a Phase 1 clinical study with preliminary data demonstrating safety and tolerability. We recently received written feedback from the FDA from a pre-IND meeting that is informing our clinical and regulatory strategy. We expect to release final data from this study in the first quarter of 2021 and then quickly start additional pre-clinical and clinical studies to support an investigational new drug application (IND) with the FDA.
-
POS back to $3.00
-
Sweet!!! Added cheap!!
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •